Clinical trial
Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19 With the Study of the Pathophysiology of the Phenomenon Using Positron Emission Tomography, Biochemical, Immunological and Electrophysiological Parameters.
NCT06012552 is registered in ClinicalTrials.gov with Military Institute od Medicine National Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19 With the Study of the Pathophysiology of the Phenomenon Using Positron Emission Tomography, Biochemical, Immunological and Electrophysiological Parameters.
- Lead sponsor
- Military Institute od Medicine National Research Institute
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- February 17, 2023
- Completion date
- October 31, 2027
- Enrollment
- 140 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.